title: A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls.
abstract: OBJECTIVE
  To measure the changes in subcutaneous and intra-abdominal fat and other metabolic parameters in patients with psychotic disorders, who were newly started on olanzapine treatment and in drug-free controls. The correlation between changes in visceral fat and other metabolic parameters were also studied.
  
  
  METHODS
  Using a longitudinal open-label design, the 2 studied groups included patients with psychoses (n = 23) [diagnosed as per the 10th edition of the International Classification of Diseases criteria] and drug-free controls (n = 11). Fasting sugar, lipid profile and glycosylated haemoglobin levels were collected at baseline and follow-up. Computed tomographic scans were used to determine changes in the various abdominal fat parameters.
  
  
  RESULTS
  The patients were significantly younger than the controls, and the former had higher mean subcutaneous fat at baseline. There were statistically significant increases in the subcutaneous fat, intraabdominal fat, weight, waist circumference, hip circumference and body mass index in patients but not in controls. The mean dose of olanzapine (mg/day) correlated significantly with change of intraabdominal fat at follow-up. The change in intra-abdominal fat did not correlate significantly with any of the metabolic parameters studied.
  
  
  CONCLUSIONS
  Olanzapine produced significant increase in weight and fat parameters. This increase correlated with the dose of olanzapine.
authors.affiliation: Department of Psychiatry, Kasturba Medical, College and Hospital, Manipal University, Manipal, Karnataka state, India. docamj81@yahoo.com
authors.forename: A M
authors.initials: AM
authors.lastname: Joseph
authors.forename: G
authors.initials: G
authors.lastname: Venkatasubramanian
authors.forename: P S
authors.initials: PS
authors.lastname: Sharma
mesh_terms: D050153:Abdominal Fat / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000378:metabolism / Q000494:pharmacology*; D001569:Benzodiazepines / Q000378:metabolism / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007194:India; D050152:Intra-Abdominal Fat / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008875:Middle Aged; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D055105:Waist Circumference / Q000187:drug effects; D049629:Waist-Hip Ratio; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D008055:Lipids; D000077152:Olanzapine